JP2018507166A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018507166A5 JP2018507166A5 JP2017528877A JP2017528877A JP2018507166A5 JP 2018507166 A5 JP2018507166 A5 JP 2018507166A5 JP 2017528877 A JP2017528877 A JP 2017528877A JP 2017528877 A JP2017528877 A JP 2017528877A JP 2018507166 A5 JP2018507166 A5 JP 2018507166A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibiotic
- conjugate compound
- alkyl
- following formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 230000003115 biocidal effect Effects 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 239000003242 anti bacterial agent Substances 0.000 claims 7
- 229940088710 antibiotic agent Drugs 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 4
- 239000004365 Protease Substances 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 4
- 125000005647 linker group Chemical group 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 229930189077 Rifamycin Natural products 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 229960003292 rifamycin Drugs 0.000 claims 3
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000000816 peptidomimetic Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical group NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 claims 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical group 0.000 claims 1
- FNXLCIKXHOPCKH-UHFFFAOYSA-N bromamine Chemical group BrN FNXLCIKXHOPCKH-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 230000001268 conjugating effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical group NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SGHWBDUXKUSFOP-KYALZUAASA-N rifalazil Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)N=C2C(=O)C=3C(O)=C4C)C)OC)C4=C1C=3C(NC1=C(O)C=3)=C2OC1=CC=3N1CCN(CC(C)C)CC1 SGHWBDUXKUSFOP-KYALZUAASA-N 0.000 claims 1
- 229950005007 rifalazil Drugs 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087213P | 2014-12-03 | 2014-12-03 | |
| US62/087,213 | 2014-12-03 | ||
| PCT/US2015/063515 WO2016090040A1 (en) | 2014-12-03 | 2015-12-02 | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018507166A JP2018507166A (ja) | 2018-03-15 |
| JP2018507166A5 true JP2018507166A5 (enExample) | 2019-01-17 |
| JP6751393B2 JP6751393B2 (ja) | 2020-09-02 |
Family
ID=55022690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528877A Expired - Fee Related JP6751393B2 (ja) | 2014-12-03 | 2015-12-02 | 抗ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ抗体リファマイシン抱合体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180125995A1 (enExample) |
| EP (1) | EP3226908A1 (enExample) |
| JP (1) | JP6751393B2 (enExample) |
| KR (1) | KR20170086542A (enExample) |
| CN (1) | CN107249642A (enExample) |
| BR (1) | BR112017011478A2 (enExample) |
| CA (1) | CA2966211A1 (enExample) |
| HK (1) | HK1244230A1 (enExample) |
| MX (1) | MX2017007231A (enExample) |
| RU (1) | RU2017118792A (enExample) |
| WO (1) | WO2016090040A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201691023A1 (ru) | 2013-12-16 | 2016-10-31 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством |
| CN105848685B (zh) | 2013-12-16 | 2020-09-22 | 健泰科生物技术公司 | 拟肽化合物及其抗体药物偶联物 |
| WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| SG10202010590UA (en) | 2015-12-04 | 2020-12-30 | Seattle Genetics Inc | Conjugates of quaternized tubulysin compounds |
| SG11201807537RA (en) * | 2016-03-04 | 2018-09-27 | Genentech Inc | Process for the preparation of an antibody-rifamycin conjugate |
| KR102835535B1 (ko) | 2016-11-08 | 2025-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 스테로이드 및 이의 단백질-접합체 |
| CN110944718A (zh) | 2017-05-18 | 2020-03-31 | 里珍纳龙药品有限公司 | 环糊精蛋白质药物偶联物 |
| AU2018365946B2 (en) * | 2017-11-07 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Hydrophilic linkers for antibody drug conjugates |
| MX2020006994A (es) | 2018-01-08 | 2020-11-06 | Regeneron Pharma | Esteroides y conjugados de anticuerpos de los mismos. |
| CN118955710A (zh) | 2018-05-09 | 2024-11-15 | 里珍纳龙药品有限公司 | 抗msr1抗体及其使用方法 |
| CN111939256B (zh) * | 2020-07-06 | 2022-05-31 | 中国药科大学 | 一种具有细菌调理特性的抗菌辅助材料及其制备方法和应用 |
| US20250082761A1 (en) * | 2021-08-20 | 2025-03-13 | Rutgers, The State University Of New Jersey | Dual-targeted rna polymerase inhibitors: conjugates of benzoxazino- and spiro-rifamycins with n alpha-aroyl-n-aryl-phenylalaninamides |
| US20250319024A1 (en) * | 2021-08-27 | 2025-10-16 | University Of Georgia Research Foundation, Inc. | Targeted nanoparticles and their uses related to infectious disease |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB877732A (en) | 1958-08-12 | 1961-09-20 | Lepetit Spa | The antibiotic rifomycin, its components and methods of preparing same |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4610919A (en) | 1985-06-14 | 1986-09-09 | Fiber Bond Corporation | Binder for fibrous padding |
| JP2544375B2 (ja) | 1986-07-14 | 1996-10-16 | 鐘淵化学工業株式会社 | アルキル置換ベンゾキサジノリフアマイシン誘導体 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| CA1304363C (en) | 1988-11-01 | 1992-06-30 | Takehiko Yamane | 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US5362852A (en) | 1991-09-27 | 1994-11-08 | Pfizer Inc. | Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties |
| US5545721A (en) | 1992-12-21 | 1996-08-13 | Ophidian Pharmaceuticals, Inc. | Conjugates for the prevention and treatment of sepsis |
| US6660267B1 (en) | 1992-12-21 | 2003-12-09 | Promega Corporation | Prevention and treatment of sepsis |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5981522A (en) | 1995-09-01 | 1999-11-09 | Kaneka Corporation | Treatment of disease caused by infection of Helicobacter |
| JP3963976B2 (ja) | 1995-12-08 | 2007-08-22 | 株式会社カネカ | クラミジア感染症治療剤 |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| US7101692B2 (en) * | 1999-04-15 | 2006-09-05 | The Regents Of The University Of California | Identification of sortase gene |
| AU5867100A (en) * | 1999-05-03 | 2000-12-12 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| WO2003002885A1 (en) * | 2001-06-28 | 2003-01-09 | Freni Brembo S.P.A. | Composite disc for a disc brake having a splittable braking band |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| EP1453837A4 (en) * | 2001-11-21 | 2007-11-07 | Activbiotics Inc | TARGETED THERAPEUTIC AGENTS AND USES THEREOF |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
| EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2502413A1 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
| EP1663107A4 (en) | 2003-08-22 | 2010-06-23 | Activbiotics Pharma Llc | RIFAMYCIN ANALOGS AND USES THEREOF |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| DK1725249T3 (en) | 2003-11-06 | 2014-03-17 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugating to ligands. |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| CN1918172B (zh) | 2003-12-23 | 2011-09-14 | 活跃生物工艺学公司 | 利福霉素类似物及其用途 |
| JP5064037B2 (ja) | 2004-02-23 | 2012-10-31 | ジェネンテック， インコーポレイテッド | 複素環式自壊的リンカーおよび結合体 |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| WO2007096703A2 (en) * | 2005-08-11 | 2007-08-30 | Targanta Therapeutics Inc. | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| BRPI0620158A2 (pt) | 2005-12-14 | 2012-04-24 | Activbiotics Pharma Llc | análogos de rifamicina e seus usos |
| CL2008001334A1 (es) | 2007-05-08 | 2008-09-22 | Genentech Inc | Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer. |
| US8937161B2 (en) | 2007-10-19 | 2015-01-20 | Genentech, Inc. | Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates |
| CA2760493A1 (en) | 2008-05-12 | 2009-11-19 | Strox Biopharmaceuticals, Llc | Staphylococcus aureus-specific antibody preparations |
| US8524691B2 (en) | 2008-08-13 | 2013-09-03 | The Medicines Company | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections |
| WO2010042481A1 (en) | 2008-10-06 | 2010-04-15 | University Of Chicago | Compositions and methods related to bacterial eap, emp, and/or adsa proteins |
| WO2010067072A1 (en) * | 2008-12-10 | 2010-06-17 | Cipla Limited | Rifaximin complexes |
| US20110020323A1 (en) * | 2009-07-15 | 2011-01-27 | Tim Beaumont | Gram-positive bacteria specific binding compounds |
| EP2678037B1 (en) | 2011-02-25 | 2014-12-03 | Lonza Ltd | Branched linker for protein drug conjugates |
| AU2012395148B2 (en) * | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| HUE050451T2 (hu) | 2013-05-31 | 2020-12-28 | Genentech Inc | Anti-fal-teichonsav antitestek és konjugátumok |
| US9884126B2 (en) * | 2013-05-31 | 2018-02-06 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
| CN105848685B (zh) * | 2013-12-16 | 2020-09-22 | 健泰科生物技术公司 | 拟肽化合物及其抗体药物偶联物 |
| EA201691023A1 (ru) * | 2013-12-16 | 2016-10-31 | Дженентек, Инк. | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством |
-
2015
- 2015-12-02 JP JP2017528877A patent/JP6751393B2/ja not_active Expired - Fee Related
- 2015-12-02 CA CA2966211A patent/CA2966211A1/en not_active Abandoned
- 2015-12-02 EP EP15816304.8A patent/EP3226908A1/en not_active Withdrawn
- 2015-12-02 MX MX2017007231A patent/MX2017007231A/es unknown
- 2015-12-02 CN CN201580075250.4A patent/CN107249642A/zh active Pending
- 2015-12-02 HK HK18103816.6A patent/HK1244230A1/zh unknown
- 2015-12-02 BR BR112017011478-0A patent/BR112017011478A2/pt not_active Application Discontinuation
- 2015-12-02 KR KR1020177015225A patent/KR20170086542A/ko not_active Withdrawn
- 2015-12-02 WO PCT/US2015/063515 patent/WO2016090040A1/en not_active Ceased
- 2015-12-02 RU RU2017118792A patent/RU2017118792A/ru not_active Application Discontinuation
-
2017
- 2017-06-02 US US15/612,193 patent/US20180125995A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507166A5 (enExample) | ||
| JP2018503603A5 (enExample) | ||
| RU2017118793A (ru) | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение | |
| RU2017118792A (ru) | Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение | |
| TWI864472B (zh) | 抗體的特異性偶聯 | |
| JP2016525343A5 (enExample) | ||
| JP2016502504A5 (enExample) | ||
| JP2018516243A5 (enExample) | ||
| JP2015527318A5 (enExample) | ||
| JP2015534580A5 (enExample) | ||
| JP2014502266A5 (enExample) | ||
| MX2021014960A (es) | Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo. | |
| JP2015534578A5 (enExample) | ||
| JP2017537893A5 (enExample) | ||
| RU2015151046A (ru) | Антитела против стеночной тейхоевой кислоты и их конъюгаты | |
| JP2017527532A5 (enExample) | ||
| JP2018511628A5 (enExample) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| EA201270738A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
| HRP20181646T2 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| JP2013512903A5 (enExample) | ||
| EA201890236A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| JP2011500725A5 (enExample) | ||
| JP2015534579A5 (enExample) |